Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
| العنوان: | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma |
|---|---|
| المؤلفون: | Jedd D. Wolchok, Jason Chesney, Christine Horak, Kenneth F. Grossmann, Matthew H. Taylor, David F. McDermott, Caroline Robert, Linda Rollin, Marc S. Ernstoff, Jeffrey K. Giguere, Montaser Shaheen, Paul Gagnier, April K.S. Salama, David R. Minor, Patrick A. Ott, Michael A. Postow, Gerald P. Linette, Sanjiv S. Agarwala, F. Stephen Hodi, Anna C. Pavlick, Nicolas Meyer |
| المصدر: | New England Journal of Medicine. 372:2006-2017 |
| بيانات النشر: | Massachusetts Medical Society, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, business.industry, Melanoma, Disease progression, Ipilimumab, General Medicine, Placebo, medicine.disease, Surgery, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, Nivolumab, business, Advanced melanoma, medicine.drug |
| الوصف: | BackgroundIn a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. MethodsIn this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. ResultsAmong patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and ni... |
| تدمد: | 1533-4406 0028-4793 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::71e4e8163ed6343ce6680b7f245708b6Test https://doi.org/10.1056/nejmoa1414428Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........71e4e8163ed6343ce6680b7f245708b6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15334406 00284793 |
|---|